AMPlify prioritizes bullfrog-genome antimicrobial peptides active against priority pathogens
Researchers integrated the attentive deep-learning classifier AMPlify into a genome-mining pipeline for North American bullfrog sequences. Of 101 candidate mature peptides generated from genome-annotated precursors, AMPlify predicted 75 as antimicrobial; 11 candidates were synthesized and tested, with four showing activity against tested bacteria, including a multidrug-resistant carbapenemase-producing E. coli isolate.
Technology: AMPlify, an attentive deep-learning antimicrobial-peptide sequence classifier
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Of 101 candidate mature peptides generated from genome-annotated precursors, AMPlify predicted 75 as antimicrobial; 11 candidates were synthesized and tested, with four showing activity against tested bacteria, including a multidrug-resistant carbapenemase-producing E. coli isolate.
- Still unknown: This is a small selected validation set: 11 of 75 model-predicted candidates were tested and four were active. Results are in vitro and do not establish therapeutic efficacy or safety. Candidate precursor identification also used homology/genome annotation; attribute AMPlify specifically to mature-peptide prioritization, not the whole discovery workflow.
- AI role: After bioinformatics identified candidate peptide precursors from the bullfrog genome, AMPlify scored 101 mature peptide sequences and nominated putative AMPs. The team selected 11 predicted peptides for synthesis and antimicrobial susceptibility testing; four showed activity against one or more of six tested bacterial strains, including the carbapenemase-producing E. coli clinical isolate.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC8788131/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 250 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.